KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Tax Provisions (2016 - 2026)

Neogenomics filings provide 14 years of Tax Provisions readings, the most recent being -$472000.0 for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 277.44% to -$472000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.0 million, a 180.43% decrease, with the full-year FY2025 number at -$2.2 million, down 15.08% from a year prior.
  • Tax Provisions hit -$472000.0 in Q1 2026 for Neogenomics, up from -$2.5 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $740000.0 in Q3 2025 to a low of -$5.7 million in Q2 2022.
  • Median Tax Provisions over the past 5 years was -$960000.0 (2023), compared with a mean of -$1.7 million.
  • Biggest five-year swings in Tax Provisions: tumbled 484.53% in 2022 and later skyrocketed 593.33% in 2025.
  • Neogenomics' Tax Provisions stood at -$2.8 million in 2022, then surged by 66.16% to -$960000.0 in 2023, then grew by 16.25% to -$804000.0 in 2024, then plummeted by 214.05% to -$2.5 million in 2025, then surged by 81.31% to -$472000.0 in 2026.
  • The last three reported values for Tax Provisions were -$472000.0 (Q1 2026), -$2.5 million (Q4 2025), and $740000.0 (Q3 2025) per Business Quant data.